[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"atopic-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:atopic-disease":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100645720","phase-1-single-ascending-and-multiple-ascending-dose-study-of-lca-0061-100645720",false,"NCT07701954","Single Ascending and Multiple Ascending Dose Study of LCA-0061","A Randomized, Double-Blind, Placebo-Controlled, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Single Doses of LCA-0061 in Atopic Healthy Participants and Multiple Doses of LCA-0061 in Participants With Peanut Allergy","Key Inclusion Criteria: Part A (SAD) and Part B (MAD)\n\n1. Must provide written consent for participation\n2. Have a body mass index (BMI) within the range of 18.0 to 30.0 kg\u002Fm2 (inclusive) and body weight ≥ 50kg at screening\n3. Have elevated serum IgE at screening\n4. Female participants of childbearing potential or male participants capable of fathering a child must be willing to use highly effective methods of contraception throughout the study and for at least 30 days after the last dose of the investigational product.\n\nPart A Only\n\n1.Must be otherwise healthy with history of atopy defined as one or more of the following: history of positive skin tests to common allergens, allergic conjunctivitis, food allergy, atopic dermatitis, urticaria\n\nPart B Only\n\n1. Be otherwise healthy with history of peanut allergy\n2. Elevated peanut-specific serum IgE within 6 months of screening\n3. Have positive skin prick test (SPT) to peanuts at screening\n\nKey Exclusion Criteria: Part A and B\n\n1. Pregnant or lactating\n2. History of clinically relevant underlying comorbidities including:\n\n   1. chronic obstructive pulmonary disease\n   2. myocardial infarction\n   3. chronic heart failure or unstable angina pectoris\n   4. hyperlipidemia\n   5. liver disease or known hepatic or biliary abnormalities \\[except Gilbert's disease or asymptomatic gallstones\\]\n   6. autoimmune or connective tissue disease\n   7. chronic inflammatory disease\n   8. persistent chronic or recurring acute infection requiring treatment with antibiotics, antivirals, or antifungals\n   9. poorly controlled atopic dermatitis requiring treatment with phototherapy, systemic immunosuppressants, or immunomodulators\n   10. Poorly controlled asthma\n   11. poorly controlled hypertension\n3. clinically significant abnormal electrocardiogram or laboratory tests (hematology, clinical chemistries, liver function tests, lipid panel, serology, or urinalysis) at screening\n4. Currently receiving immunotherapy for food allergies\n5. Use of nicotine containing products (excluding nicotine patches or gum for smoking cessation) within 6 months prior to screening.\n6. Positive test for alcohol or illicit drugs at screening or prior to dosing.\n7. Other conditions or concomitant medications that are excluded by the protocol, or in the opinion of the investigator, or sponsor representative, would pose a risk to participant safety or interfere with the study evaluation, procedures, or completion.","ALL","18 Years","55 Years",{"count":20,"type":21},72,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","This is a Phase 1combined single ascending dose (SAD)\u002Fmultiple ascending dose (MAD) randomized, double-blind, placebo-controlled trial to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of single and multiple ascending subcutaneous doses of LCA-0061in participants with atopic conditions (SAD) and participants with peanut allergy (MAD).",[27,28],"Atopic Disease","Peanut Allergies","RECRUITING","2026-07-13",{"date":32,"type":33},"2026-07-14","ACTUAL",{"date":35,"type":33},"2026-06-26",{"date":37,"type":21},"2028-04",{"name":39,"class":40},"Lycia Therapeutics, Inc.","INDUSTRY",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":56,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":5},"100596932","microbiome-and-atopy-in-mali-100596932","NCT07051902","Microbiome and Atopy in Mali","Analyzing the Microbiome and Environmental Exposures of Patients Suffering From Atopic Diseases in Mali","Inclusion Criteria (Study Group):\n\n* Aged ≥3 years.\n* Able to provide informed consent (for ages ≥18 years) or has a parent or guardian who can provide informed consent on their behalf (for ages \\\u003C18 years).\n* Positive Screening questionnaire for asthma or eczema.\n* Diagnosed with atopic dermatitis or asthma via physician diagnosis and criteria as follows:\n* Clinical diagnosis of atopic disease, as defined by Hanifin and Rajka criteria, that has been present for ≥3 months before the screening visit.\n\nInclusion Criteria (Healthy Volunteers):\n\n* Aged ≥3 years.\n* Able to provide informed consent (for ages ≥18 years) or has a parent or guardian who can provide informed consent on their behalf (for ages \\\u003C18 years).\n* Negative Screening questionnaire for asthma and eczema.\n* In good general health as evidenced by medical history and not diagnosed with atopic dermatitis or asthma via physician diagnosis.\n* Failure to meet Hanifin and Rajka criteria and \\\u003C3 on GINA guidelines for asthma diagnosis.\n* No self-reported history of food allergy.\n\nExclusion Criteria:\n\n* Use of antibiotics in the 3 months prior to screening.\n* Current pregnancy or lactation (determined by self-report).\n* Treatment with an investigational drug within 12 months prior to screening.\n* Current smoker or tobacco use within 4 months prior to screening.\n* Current skin infections other than atopic dermatitis (e.g., scabies).\n* Active diarrhea as defined by three or more loose stools per day (Bristol stool scale score of 6 or 7).\n* Presence of current bacterial, viral, or fungal infection, with the exception of isolated onchomycosis, which is not exclusionary.\n* Any other condition or factor that the investigator determines may significantly influence the results of testing.",true,"3 Years",{"count":52,"type":21},288,"OBSERVATIONAL","This study is about allergic diseases in people living in Mali. Allergic diseases can cause health problems like asthma or skin rashes. In this study, the investigators will look for clues about things that may affect whether people get allergic diseases. The investigators will look at things on or in the body, like germs, and things in the environment, like pollution. To do this, the investigators will collect different types of biological samples, health information, and environmental information from people with allergic diseases and people without allergic diseases. The investigators will compare what is found in each group to look for differences that might be related to allergic disease.",[27],[57,58,59],"asthma","atopic dermatitis","allergies","2026-04-10",{"date":62,"type":33},"2026-04-15",{"date":64,"type":33},"2025-09-30",{"date":66,"type":21},"2026-12",{"name":68,"class":69},"National Institute of Allergy and Infectious Diseases (NIAID)","NIH"]